Atossa Therapeutics (ATOS) Operating Expenses (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Operating Expenses of $9.9 million for Q1 2026, up 33.13% year-over-year from $7.4 million in Q1 2025, and down 13.69% quarter-over-quarter from $11.4 million in Q4 2025.
Atossa Therapeutics (ATOS) Operating Expenses (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Operating Expenses for 16 consecutive years, with $9.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 33.13% year-over-year to $9.9 million; the TTM figure through Mar 2026 stood at $39.6 million (up 41.14% YoY), while the FY2025 annual figure was $37.1 million, up 34.47% from the prior year.
- Operating Expenses declined to $9.9 million in Q1 2026 per ATOS's latest filing, from $11.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $11.4 million in Q4 2025 and bottomed at $4.7 million in Q1 2022.
- Historically, Operating Expenses has averaged $7.9 million across 5 years, with a median of $7.5 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 68.56% — and 2024, when it retreated 20.71%.
- Atossa Therapeutics' Operating Expenses stood at $8.1 million in 2022, then increased by 10.83% to $9.0 million in 2023, then declined by 20.71% to $7.2 million in 2024, then surged by 59.92% to $11.4 million in 2025, then decreased by 13.69% to $9.9 million in 2026.
- Business Quant data shows ATOS's Operating Expenses at $9.9 million in Q1 2026, $11.4 million in Q4 2025, and $9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 541.02 Mn |
| 10 | Atossa Therapeutics | 22.98 Mn | 22.98 Mn | - | 8.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.69 Mn |
| Mar 31, 2026 | 9.87 Mn |
| Dec 31, 2025 | 11.44 Mn |
| Sep 30, 2025 | 9.25 Mn |
| Jun 30, 2025 | 9.04 Mn |
| Mar 31, 2025 | 7.41 Mn |
| Dec 31, 2024 | 7.15 Mn |
| Sep 30, 2024 | 6.39 Mn |
| Jun 30, 2024 | 7.11 Mn |
| Mar 31, 2024 | 6.98 Mn |
| Dec 31, 2023 | 9.02 Mn |
| Sep 30, 2023 | 7.47 Mn |
| Jun 30, 2023 | 7.79 Mn |
| Mar 31, 2023 | 7.10 Mn |
| Dec 31, 2022 | 8.14 Mn |
| Sep 30, 2022 | 8.21 Mn |
| Jun 30, 2022 | 6.60 Mn |
| Mar 31, 2022 | 4.75 Mn |
| Dec 31, 2021 | 4.83 Mn |
| Sep 30, 2021 | 5.16 Mn |